

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Gertrude K. McFarland, FAAN, RN, DNSC, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3156, MSC 7770, Bethesda, MD 20892, (301) 435-1784, [mcfarlag@csr.nih.gov](mailto:mcfarlag@csr.nih.gov).

*Name of Committee:* AIDS and Related Research Integrated Review Group; AIDS-associated Opportunistic Infections and Cancer Study Section.

*Date:* March 19, 2007.

*Time:* 8 a.m. to 6:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Watergate Hotel, 2650 Virginia Avenue, NW., Washington, DC 20037.

*Contact Person:* Eduardo A. Montalvo, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5212, MSC 7852, Bethesda, MD 20892, (301) 435-1168, [montalve@csr.nih.gov](mailto:montalve@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Infectious Diseases and Microbiology Fellowships.

*Date:* March 19-20, 2007.

*Time:* 8:30 a.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* St. Gregory Hotel, 2033 M Street, NW., Washington, DC 20036.

*Contact Person:* John C. Pugh, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3114, MSC 7808, Bethesda, MD 20892, (301) 435-2398, [pughjohn@csr.nih.gov](mailto:pughjohn@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Regulation of Axonal Growth and Synaptic Plasticity.

*Date:* March 19, 2007.

*Time:* 11 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Lawrence Baizer, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4152, MSC 7850, Bethesda, MD 20892, (301) 435-1257, [baizerl@csr.nih.gov](mailto:baizerl@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Neurogenesis and Stem Cells.

*Date:* March 19, 2007.

*Time:* 2 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Joanne T. Fujii, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4184, MSC 7850, Bethesda, MD 20892, (301) 435-1178, [fujii@csr.nih.gov](mailto:fujii@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR-06-389: Basic and Translational Research

Opportunities in the Social Neuroscience of Mental Health.

*Date:* March 20-21, 2007.

*Time:* 6 a.m. to 7 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Jane A. Doussard-Roosevelt, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, MSC 7848, Bethesda, MD 20892, (301) 435-4445, [doussarj@csr.nih.gov](mailto:doussarj@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR-06-473 Translational Research on the Relationship of Anxiety and Depression (R21).

*Date:* March 20-21, 2007.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Maribeth Champoux, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3146, MSC 7759, Bethesda, MD 20892, 301-594-3163, [champoum@csr.nih.gov](mailto:champoum@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Small Business: Neural System.

*Date:* March 20, 2007.

*Time:* 2 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Bernard F. Driscoll, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5184, MSC 7844, Bethesda, MD 20892, (301) 435-1242, [driscolb@csr.nih.gov](mailto:driscolb@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Heart Failure.

*Date:* March 20, 2007.

*Time:* 2:30 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Maqsood A. Wani, PhD, DVM, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2114, MSC 7814, Bethesda, MD 20892, 301-435-2270, [wanimags@csr.nih.gov](mailto:wanimags@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Social Sciences.

*Date:* March 21, 2007.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Ann Hardy, DRPH, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3158, MSC 7770, Bethesda, MD 20892, (301) 435-0695, [hardyan@csr.nih.gov](mailto:hardyan@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Cognition.

*Date:* March 21, 2007.

*Time:* 2 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Bernard F. Driscoll, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5184, MSC 7844, Bethesda, MD 20892, (301) 435-1242, [driscolb@nih.gov](mailto:driscolb@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; BGES Special Emphasis Panel Study Section-HOP E 02 M.

*Date:* March 21, 2007.

*Time:* 4 p.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Karin F. Helmers, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3166, MSC 7770, Bethesda, MD 20892, (301) 435-1017, [helmersk@csr.nih.gov](mailto:helmersk@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 15, 2007.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-835 Filed 2-23-07; 8:45am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Use of Recombinant Yeast Expressing CEA for the Prevention and Treatment of Cancer

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive

patent license to practice the inventions embodied in U.S. Patent 6,756,038 and PCT Application Serial No. PCT/US98/19794 and foreign equivalents thereof, entitled "Agonist and Antagonist Peptides of Carcinoembryonic Antigen (CEA)" (E-099-1996/0) and U.S. Patent 6,969,582 and PCT Application Serial No. PCT/US99/26866 and foreign equivalents thereof, entitled "A Recombinant Vector Expressing Multiple Costimulatory Molecules and Uses Thereof" (E-256-1998/0), to GlobeImmune Inc., which is located in Louisville, Colorado. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the use recombinant *Saccharomyces cerevisiae* expressing CEA for the prevention and treatment of cancer.

**DATES:** Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 27, 2007 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Michelle A. Booden, PhD., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 451-7337; Facsimile: (301) 402-0220; E-mail: [boodenm@mail.nih.gov](mailto:boodenm@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** The technology describes the composition and use of nucleic acid sequences that encode agonist and one antagonist peptide variants of the human carcinoembryonic antigen (CEA) peptide, including but not limited to CAP-1. CEA is an antigen, which is expressed on the surface of various types of cancer cells. It is capable of stimulating a specific cytolytic T cell response, as is CAP-1, which is a highly immunogenic epitope of CEA. Therefore, CAP-1 agonists which are capable of eliciting a CEA-specific cytolytic T cell response, such as those identified by the inventors, may represent potential immunogens for use as therapeutic agents or vaccines against various cancers, and possibly also for use against autoimmune diseases. In fact, at least one of the agonist peptides appears to be more immunogenic than the native CAP-1 peptide. CAP-1 antagonists which are capable of reducing or eliminating this T cell response, such as the antagonist peptide variant identified by the inventors, may

represent potential agents for use against autoimmune responses to CEA or to agonist peptide variants thereof.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR Part 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 16, 2007.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E7-3153 Filed 2-23-07; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of General Medical Sciences 2008-2012 Strategic Plan

**ACTION:** Notice with request for comments.

**SUMMARY:** NIGMS is initiating a strategic planning process that will culminate in the NIGMS Strategic Plan for 2008-2012. To assist with this process, NIGMS requests input from scientists, scientific organizations, and other interested parties. The goal of this strategic planning process is to identify Institute priorities and guide decision-making over the next five years. Information about NIGMS can be found at <http://www.nigms.nih.gov/>.

**DATES:** In order to ensure full consideration, responses must be submitted by 12 midnight EDT on March 20, 2007.

**ADDRESSES:** Interested individuals and organizations should submit their responses to <http://www.nigms.nih.gov/About/StrategicPlan/Input.htm>.

**SUPPLEMENTARY INFORMATION:**

## Background

The mission of the National Institute of General Medical Sciences (NIGMS) is to support basic research whose results lay the foundation for the diagnosis, treatment, and prevention of disease. NIGMS-funded researchers seek to answer important questions in fields such as cell biology, biophysics, genetics, developmental biology, pharmacology, physiology, biochemistry, chemistry, bioinformatics, and computational biology, and in selected cross-cutting clinical areas that affect multiple organ systems. NIGMS also provides leadership in promoting the diversity of the scientific workforce and in training the next generation of scientists to assure the vitality and continued productivity of basic research.

NIGMS has embarked on a strategic planning process to identify Institute priorities to guide decision-making over the next five years. To assure the broadest possible input, NIGMS is inviting the scientists, scientific organizations, and other interested parties to respond electronically to a series of questions, listed below.

- What factors should NIGMS consider in deciding how to set its priorities with respect to new and existing areas of support?
  - What factors should NIGMS consider in deciding how to set its priorities with respect to research training?
    - What new or emerging areas, approaches, or technologies in basic biomedical research should NIGMS pursue?
    - As part of its efforts to maintain a balanced research portfolio, how can NIGMS best encourage and support research that is highly innovative and/or risky?
    - Are there areas of current NIGMS research activity that should receive less emphasis?
    - How can NIGMS enhance its communication with the scientific community and the public?
    - How can NIGMS more effectively promote and encourage greater diversity in the biomedical research workforce?
- You may also submit other comments relevant to NIGMS that are not specifically addressed in these questions.

Responses will be limited to approximately 500 words per question. All information provided will be processed and analyzed with strict anonymity.

*Contact Person:* Judith H. Greenberg, PhD., National Institute of General Medical Sciences, National Institutes of